DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR AMILORIDE HYDROCHLORIDE
Clinical Trials for Amiloride Hydrochloride
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00004705 | Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis | Completed | University of North Carolina | N/A | OBJECTIVES: I. Determine the stability of uridine triphosphate (UTP) and examine the metabolism of exogenous nucleotides on airway epithelial surfaces in patients with cystic fibrosis. II. Determine the acute safety and efficacy of aerosolized UTP in children with cystic fibrosis. |
NCT00004705 | Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis | Completed | FDA Office of Orphan Products Development | N/A | OBJECTIVES: I. Determine the stability of uridine triphosphate (UTP) and examine the metabolism of exogenous nucleotides on airway epithelial surfaces in patients with cystic fibrosis. II. Determine the acute safety and efficacy of aerosolized UTP in children with cystic fibrosis. |
NCT00007592 | Hypertension Screening and Treatment Program | Completed | VA Office of Research and Development | N/A | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. |
NCT00141596 | Extracellular Fluid in Resistant Hypertension | Terminated | St George's, University of London | N/A | The optimal treatment of drug resistant (defined as BP> 140/85 despite three anti-hypertensive drugs including a diuretic) is not well defined. This study aims to test the hypothesis that resistant hypertension is caused by excessive expansion of extracellular fluid volume. A secondary objective is to study which of three different antihypertensive drugs would be most useful in drug resistant hypertension. |
Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Amiloride Hydrochloride
Condition Name
Condition MeSH
Clinical Trial Locations for Amiloride Hydrochloride
Trials by Country
Clinical Trial Progress for Amiloride Hydrochloride
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Amiloride Hydrochloride
Sponsor Name